Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review
ConclusionsAlthough targeted therapies demonstrate systemic benefits for patients with NSCLC, BrMs, and AGAs, there remains a continued need for effective therapies to treat and prevent BrMs in this population. Increased BBB permeability of emerging therapies may improve outcomes for this population.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Databases & Libraries | Drugs & Pharmacology | Lung Cancer | Lymphoma | Neurology | Non-Small Cell Lung Cancer | Study | Toxicology